Sofinnova et al. back €27m series-C for Limflow

The round, led by Sofinnova Partners, also saw BPI France and Balestier, a Singaporean family fund, backing Limflow. 

Gérard Hascöet, Partner at Sofinnova Partners, and Kinam Hong, Partner of the Sofinnova Crossover I Fund, will join the company’s board.

Sofinnova’s Crossover Fund I held a first close earlier this month on €275m. The vehicle focuses on companies with EVs of €50-150m and provides equity tickets of €15-20m, investing a maximum of €25m per company.

The company will use the fresh capital for its product development and geographical expansion.

Company
LimFlow is a medical device company transforming the treatment of Critical Limb Ischemia, a growing clinical need in the face of the prevalence of diabetes, heart disease and an aging population. Founded in 2012, it is based in Paris and has also facilities in the US.

People
Limflow - Dan Rose (CEO).
Sofinnova Partners - Antoine Papiernik (chair); Jacques Theurillat (partner).

 

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Expansion
• France
• Healthcare
• France
• Sofinnova
• Venture